Alpha-MSH vs LL-37

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Human cathelicidin antimicrobial peptide; disrupts bacterial membranes and modulates innate immune response via TLR signaling

LL-37 is the mature human cathelicidin antimicrobial peptide, a 37-amino-acid cationic peptide generated by proteolytic cleavage of the hCAP18 precursor protein, constitutively expressed in neutrophil granules and inducibly expressed in keratinocytes and epithelial cells of the skin, lung, and gastrointestinal tract as a component of innate antimicrobial defense. LL-37 disrupts bacterial and fungal membranes through electrostatic interaction with anionic lipopolysaccharide and membrane phospholipids, and also modulates inflammatory responses through formyl peptide receptor 2 (FPR2/ALX) activation, promotes wound healing via EGFR transactivation, and contributes to neutrophil extracellular trap formation and antiviral defense. Human studies have documented LL-37 expression in the context of severe soft tissue infections caused by Streptococcus pyogenes, and biochemical characterization of the hCAP18/LL-37 prosequence has identified antimicrobial and protease-inhibitory functions relevant to human skin defense biology. LL-37 is a research compound with no FDA approval for any indication; exogenous synthetic LL-37 administration is investigational with no completed human clinical trials establishing safety or efficacy for wound healing, antimicrobial, or immunomodulatory applications. LL-37 dosage and administration: No human clinical trial has established a dosage protocol for exogenous LL-37. Preclinical and in vitro studies have used LL-37 at concentrations ranging from 1–50 µg/mL in cellular models. Animal models have employed weight-based dosing via subcutaneous or intravenous delivery. Topical formulations for wound healing and antimicrobial applications have been investigated at varying concentrations, with interest in hydrogel delivery systems for sustained local release. LL-37 is rapidly degraded by host proteases in vivo, which limits systemic bioavailability following subcutaneous injection; this degradation susceptibility has driven research into protease-resistant LL-37 analogues and encapsulated formulations. LL-37 is a research compound with no approved human dosing guidelines for any indication.